Subscribe
istock-855160904casarsaguru
CasarsaGuru / iStockphoto.com
30 July 2018Biotechnology

CJEU gene-editing decision ‘could stifle’ innovation in Europe

A ruling handed down last week by the Court of Justice of the European Union (CJEU) could stifle innovation in the gene-editing field, causing Europe to lag behind the rest of the world, commentators say.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
CJEU tightens gene-editing rules with GMO decision
26 July 2018   Genome-editing techniques, including CRISPR/Cas9, will be subject to more stringent regulations after a ruling from Europe’s highest court yesterday.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

More on this story

Biotechnology
CJEU tightens gene-editing rules with GMO decision
26 July 2018   Genome-editing techniques, including CRISPR/Cas9, will be subject to more stringent regulations after a ruling from Europe’s highest court yesterday.

More on this story

Biotechnology
CJEU tightens gene-editing rules with GMO decision
26 July 2018   Genome-editing techniques, including CRISPR/Cas9, will be subject to more stringent regulations after a ruling from Europe’s highest court yesterday.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent